Successful Generation of Donor Specific Hematopoietic Stem Cell Lines From Co-Cultured Bone Marrow With Human Embryonic Stem Cell Line: A New Methodology

Vanikar, Aruna V; Mishra, V V; Firoz, Ahad; Shah, Veena R; Dave, Shruti D; Patel, Rashmi D; Kanodia, Kamal V; Patel, J. D.; Patel, Chirag H.; Trivedi, HL

doi:10.1016/j.transproceed.2007.01.048

Cited by 9 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A primary thrust of investigations focused on megakaryopoiesis and thrombopoiesis has been to identify culture mediums, cytokine cocktails, and extracellular matrices that yield high numbers of platelets with morphologic characteristics and functions similar to platelets that are freshly isolated from the bloodstream. Results from these studies indicate that slight alterations in the in vitro culture conditions and/or constituents can significantly influence the generation and phenotype of newly formed platelets [17][18][19][20][21][22][23]. This strongly suggests that changes in the bone marrow milieu can alter transcriptional, translational, and post-translational processes throughout megakaryocyte development, differentiation, and proplatelet formation.…”

Section: Megakaryopoiesis and Thrombopoiesis: Key Determinants Of Thementioning

confidence: 97%

Regulation of the genetic code in megakaryocytes and platelets

Rondina

Weyrich

2015

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Summary Platelets are generated from nucleated precursors referred to as megakaryocytes. The formation of platelets is one of the most elegant and unique developmental processes in eukaryotes. Because they enter the circulation without nuclei, platelets are often considered simple, non-complex cells that have limited functions beyond halting blood flow. However, emerging evidence over the past decade demonstrates that platelets are more sophisticated than previously considered. Platelets carry a rich repertoire of messenger RNAs (mRNAs), microRNAs (miRNAs), and proteins that contribute to primary (adhesion, aggregation, secretion) and alternative (immune regulation, RNA transfer, translation) functions. It is also becoming increasing clear that the “genetic code” of platelets changes with race, genetic disorders, or disease. Changes in the “genetic code” can occur at multiple points including megakaryocyte development, platelet formation, or in circulating platelets. This review focuses on regulation of the “genetic code” in megakaryocytes and platelets and its potential contribution to health and disease.

show abstract

Section: Megakaryopoiesis and Thrombopoiesis: Key Determinants Of Thementioning

confidence: 97%

Regulation of the genetic code in megakaryocytes and platelets

Rondina

Weyrich

2015

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…The derived cells resulted in an alternative source of CD34-positive stem cells to treat autoimmune disorders. 64 A second method for delivering genetically modified cells would be the use of viral vectors with the hESCs (ex vivo gene therapy) that can be used before transplanting the cells into the brain to deliver GNDF, brain-derived neurotrophic factor (BDNF), or some other neurotrophic factor for neuroprotective or neurorestorative procedures. Altering the genetic make-up of the cells to be neurotrophic mini-pumps once transplanted, might be safer than direct, in vivo, gene therapy, because this avoids the introduction of unwanted vector proteins into the host brain and can induce the desired phenotype ex vivo without the risk of inflammatory response by the host.…”

Section: Involvement Of Hescs In Treating Pdmentioning

confidence: 99%

Therapeutic Potentials of Human Embryonic Stem Cells in Parkinson’s Disease

Newman

Bakay

2008

Neurotherapeutics

View full text Add to dashboard Cite

Summary:The loss of dopaminergic neurons of the substantia nigra is the pathological hallmark characteristic of Parkinson's disease (PD). The strategy of replacing these degenerating neurons with other cells that produce dopamine has been the main approach in the cell transplantation field for PD research. The isolation, differentiation, and long-term cultivation of human embryonic stem cells and the therapeutic research discovery made in relation to the beneficial properties of neurotrophic and neural growth factors has advanced the transplantation field beyond dopamine-producing cells. The present review addresses recent advances in human embryonic stem cell experimentation in relation to treating PD, as well as cell transplantation techniques in conjunction with alternative therapeutics.

show abstract

“…The need for saviour embryos may lapse if it proves possible to derive suitable tissue for the appropriate transplants from embryos created using somatic cell nuclear transfer (SCNT) of DNA from a person who was HLA-compatible with the child requiring a transplant (Elsner, 2006;Vanikar et al, 2007) or from 'induced pluripotent stem (IPS) cells' created from such a person (Baker, 2007;Takahashi et al, 2007;Yu et al, 2007). The latter technology would clearly be preferable, if it becomes available, as it would avoid the creation of a human embryo (some ethical concerns about SCNT cloning are discussed below).…”

Section: The Case For Saviour Embryosmentioning

confidence: 99%